I am a clinical pharmacologist studying how pharmacogenetic test results change prescribing and patient outcomes. I combine Danish national registry data with prospective clinical trials to measure whether genotype-guided dosing reduces adverse drug reactions and treatment failures.
My current work focuses on CYP2C19-guided antiplatelet therapy, SLCO1B1 genotyping for statin intolerance, and therapeutic drug monitoring of targeted cancer therapies.
Experience
Fellow in Clinical Pharmacology | 2023 to 2028
- Department of Genomic Medicine, Rigshospitalet (current)
- Department of Endocrinology, Herlev Hospital
- Cardiovascular Medical and Science, Novo Nordisk
Postdoctoral Researcher | Department of Clinical Pharmacology, Bispebjerg Hospital
Education
PhD in Medical Science | University of Copenhagen | 2016 to 2020
- Thesis: Real-world evidence on the risk, type and treatment of infectious complications in chronic lymphocytic leukaemia
Medical Doctor (MD) | University of Copenhagen | 2008 to 2015
Positions
- Chair, Danish Society for Personalized Medicine (2025 to present)
- Editor, Frontiers in Epidemiology (2023 to present)
- Member, Clinical Pharmacogenetics Implementation Consortium (CPIC) (2022 to present)
- Member, Pharmacogenomics Global Research Network (2022 to present)